Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OGA | O60502 | 3/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | PSEN1 | P49768 | 3/20 | 0.32 |
| ▸ | PSEN2 | P49810 | 3/20 | 0.32 |
| ▸ | APH1B | Q8WW43 | 3/20 | 0.32 |
| ▸ | NCSTN | Q92542 | 3/20 | 0.32 |
| ▸ | APH1A | Q96BI3 | 3/20 | 0.32 |
| ▸ | PSENEN | Q9NZ42 | 3/20 | 0.32 |
| ▸ | SSTR4 | P31391 | 3/20 | 0.32 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.30 |
| ▸ | DPP4 | P27487 | 1/20 | 0.30 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24928079 | 1.00 | OGA (0.36) | OGAMAPK1SMN1; SMN2NPSR1CYP2C9 | |
| SCHEMBL10513011 | 1.00 | OGA (0.36) | OGAMAPK1SMN1; SMN2NPSR1CYP2C9 | |
| SCHEMBL25680916 | 0.85 | OGA (0.41) | OGASMN1; SMN2NPSR1CYP2C9CYP2C19 | |
| SCHEMBL21564569 | 0.83 | SSTR4 (0.44) | OGAPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL23260101 | 0.78 | PSEN1 (0.34) | OGASMN1; SMN2NPSR1CYP2C9CYP2C19 | |
| SCHEMBL23260093 | 0.78 | PSEN1 (0.34) | OGASMN1; SMN2NPSR1CYP2C9CYP2C19 | |
| SCHEMBL22296255 | 0.78 | EGFR (0.37) | MAPK1SSTR4SSTR1 | |
| SCHEMBL25022569 | 0.78 | SSTR4 (0.39) | OGAMAPK1SMN1; SMN2NPSR1CYP2C9 | |
| SCHEMBL25022640 | 0.78 | SSTR4 (0.39) | OGAMAPK1SMN1; SMN2NPSR1CYP2C9 | |
| SCHEMBL8280849 | 0.78 | OGA (0.41) | OGASMN1; SMN2NPSR1CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230029385-A1 | 2-METHYL-AZA-QUINAZOLINES | BAYER AG (DE) | 2023-01-26 | — | — | US | disclosed |
| EP-0191451-B1 | NOVEL 1,8-NAPHTHYRIDINE DERIVATIVES AND PROCESSES FOR PREPARATION THEREOF | Dainippon Pharmaceutical Co., Ltd. (JP) | 1989-08-02 | — | — | EP | disclosed |
| EP-0191451-A1 | Novel 1,8-naphthyridine derivatives and processes for preparation thereof | Dainippon Pharmaceutical Co., Ltd. (JP) | 1986-08-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230029385-A1 | 2-METHYL-AZA-QUINAZOLINES | AZI2, DNMT1, TPMT | OGA 2673/4885MAPK1 2680/4885SMN1; SMN2 1633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.